Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2013. The report details a specific share repurchase transaction executed on December 2, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 864,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price of 1,626.00 pence per share; lowest price of 1,614.50 pence per share.
- Treasury Holdings (Settled): 510,797,909 shares (9.51% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,146,909 shares (10.56% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,860,906,132 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 864,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.56% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (510,797,909 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.56% held in treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (4,860,906,132 shares in issue excluding treasury).
- Review the price paid per share (1,614.50 to 1,626.00 pence) against market prices on December 2, 2013.